Chris P. Recknor
2022
In 2022, Chris P. Recknor earned a total compensation of $1.9M as Sr. Executive VP of Clinical Operations at CytoDyn.
Compensation breakdown
| Option Awards | $1,452,900 |
|---|---|
| Salary | $436,042 |
| Stock Awards | $23,960 |
| Other | $13,081 |
| Total | $1,925,983 |
Recknor received $1.5M in option awards, accounting for 75% of the total pay in 2022.
Recknor also received $436K in salary, $24K in stock awards and $13.1K in other compensation.
Rankings
In 2022, Chris P. Recknor's compensation ranked 1,817th out of 5,760 executives tracked by ExecPay. In other words, Recknor earned more than 68.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,817 out of 5,760 | 69th |
Division Manufacturing | 954 out of 3,136 | 70th |
Major group Chemicals And Allied Products | 388 out of 1,422 | 73rd |
Industry group Drugs | 354 out of 1,323 | 73rd |
Industry Pharmaceutical Preparations | 254 out of 969 | 74th |
Source: SEC filing on October 26, 2022.
Recknor's colleagues
We found four more compensation records of executives who worked with Chris P. Recknor at CytoDyn in 2022.